These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1972 related items for PubMed ID: 16810614

  • 21. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.
    Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY, Wadleigh M, Gary Gilliland D.
    Br J Haematol; 2005 Nov; 131(3):320-8. PubMed ID: 16225651
    [Abstract] [Full Text] [Related]

  • 22. Elevated serum erythropoietin levels in patients with Budd-Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis.
    Thurmes PJ, Steensma DP.
    Eur J Haematol; 2006 Jul; 77(1):57-60. PubMed ID: 16827884
    [Abstract] [Full Text] [Related]

  • 23. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
    Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, Li S, Van Etten RA.
    PLoS One; 2006 Dec 20; 1(1):e18. PubMed ID: 17183644
    [Abstract] [Full Text] [Related]

  • 24. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H, Bödör C, Reiniger L, Timár B, Csernus B, Szepesi A, Csomor J, Matolcsy A.
    Orv Hetil; 2006 Nov 12; 147(45):2175-9. PubMed ID: 17402211
    [Abstract] [Full Text] [Related]

  • 25. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A.
    Am J Hematol; 2012 Mar 12; 87(3):285-93. PubMed ID: 22331582
    [Abstract] [Full Text] [Related]

  • 26. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.
    Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R, Li CY, Wadleigh M, Lee SJ, Gilliland DG.
    Cancer; 2006 Feb 01; 106(3):631-5. PubMed ID: 16369984
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K, Shimoda K.
    Rinsho Byori; 2009 Apr 01; 57(4):357-64. PubMed ID: 19489438
    [Abstract] [Full Text] [Related]

  • 30. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation.
    Aboudola S, Murugesan G, Szpurka H, Ramsingh G, Zhao X, Prescott N, Tubbs RR, Maciejewski JP, Hsi ED.
    Am J Surg Pathol; 2007 Feb 01; 31(2):233-9. PubMed ID: 17255768
    [Abstract] [Full Text] [Related]

  • 31. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
    Malak S, Labopin M, Saint-Martin C, Bellanne-Chantelot C, Najman A, French Group of Familial Myeloproliferative Disorders.
    Blood Cells Mol Dis; 2007 Feb 01; 49(3-4):170-6. PubMed ID: 22818858
    [Abstract] [Full Text] [Related]

  • 32. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.
    Tefferi A, Sirhan S, Lasho TL, Schwager SM, Li CY, Dingli D, Wolanskyj AP, Steensma DP, Mesa R, Gilliland DG.
    Br J Haematol; 2005 Oct 01; 131(2):166-71. PubMed ID: 16197445
    [Abstract] [Full Text] [Related]

  • 33. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H.
    Exp Hematol; 2009 Oct 01; 37(10):1186-1193.e7. PubMed ID: 19616600
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.
    Rudzki Z, Sacha T, Stój A, Czekalska S, Wójcik M, Skotnicki AB, Grabowska B, Zduńczyk A, Okoń K, Stachura J.
    Int J Hematol; 2007 Aug 01; 86(2):130-6. PubMed ID: 17875526
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Expertise-based management in essential thrombocythemia and polycythemia vera.
    Finazzi G, Barbui T.
    Cancer J; 2007 Aug 01; 13(6):372-6. PubMed ID: 18032974
    [Abstract] [Full Text] [Related]

  • 38. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
    Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P.
    Semin Thromb Hemost; 2006 Jun 01; 32(4 Pt 2):417-21. PubMed ID: 16810617
    [Abstract] [Full Text] [Related]

  • 39. Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation.
    Spivak JL.
    Ann Intern Med; 2010 Mar 02; 152(5):300-6. PubMed ID: 20194236
    [Abstract] [Full Text] [Related]

  • 40. [Acquired mutation of JAK2 tyrosine kinase and polycythaemia vera].
    Pargade V, Darnige L, Gaussem P.
    Ann Biol Clin (Paris); 2006 Mar 02; 64(1):3-9. PubMed ID: 16420986
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 99.